Medifast (NYS: MED) is expected to report Q1 earnings on May 8. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Medifast's revenues will grow 6.3% and EPS will grow 6.3%.
The average estimate for revenue is $94.5 million. On the bottom line, the average EPS estimate is $0.34.
Last quarter, Medifast tallied revenue of $83.2 million. GAAP reported sales were 20% higher than the prior-year quarter's $69.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.28. GAAP EPS of $0.14 for Q4 were 75% higher than the prior-year quarter's $0.08 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.4%, 20 basis points better than the prior-year quarter. Operating margin was 12.7%, much better than the prior-year quarter. Net margin was 2.2%, 50 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $390.1 million. The average EPS estimate is $1.77.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 252 members out of 305 rating the stock outperform, and 53 members rating it underperform. Among 65 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give Medifast a green thumbs-up, and 19 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medifast is outperform, with an average price target of $34.40.
Looking for alternatives to Medifast? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
Add Medifast to My Watchlist.
The article Will Medifast Beat These Analyst Estimates? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.